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Abstract A 46-year-old male was found to have protein-
uria on a routine medical examination in 1985 at the age of
22 years and was diagnosed with immunoglobulin A (IgA)
nephropathy by renal biopsy. He regularly visited a hospital,
but 3 years later made the decision to stop. In 2000, his serum
creatinine level was 1.3 mg/dl. His renal function then
deteriorated, with persistent proteinuria and hematuria, fol-
lowing which he visited our hospital in December 2008. A
further renal biopsy was performed. Active and chronic IgA
nephropathy was confirmed histologically, with sclerosing
lesions also being found. He was treated with three courses of
steroid pulse therapy in February and tonsillectomy in April
2009. During the follow-up period at the outpatient clinic,
results for proteinuria and hematuria were negative, sug-
gesting that progression of renal impairment had been pre-
vented. The efficacy of tonsillectomy plus steroid pulse
therapy for early IgA nephropathy has been demonstrated,
and this treatment was effective in our patient 20 years after
the onset of the disease.
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Introduction
In 1968, Berger et al. reported that immunoglobulin A
(IgA) nephropathy had a favorable prognosis. However,
this prognosis was questioned in a report published in
1993, which showed that 10–15 % of patients with IgA
nephropathy developed end-stage renal disease (ESRD)
within 10 years and 40 % after 20 years [1]. The Ministry
of Health, Labor and Welfare and Japanese Society of
Nephrology considered the disease a matter of great con-
cern and jointly developed the clinical guidelines for IgA
nephropathy in Japan (first published in 1995, the second
version in 2002 [2] and the third version in 2011 [3]).
These clinical guidelines recommend intervention after
careful evaluation of disease activity and treatment. These
recommendations are based on a report [4] showing that
20 % of patients recovered spontaneously, with 40 % not
progressing to renal impairment.
There are several reports on the efficacy of tonsillec-
tomy and steroid pulse therapy for early stage IgA
nephropathy [5, 6], although little is known concerning the
best treatment for advanced stage IgA nephropathy.
Case report
A 43-year old male presented with a history of proteinuria
discovered on a routine medical examination in 1985 when
he was 22 years old. His medical history was acute pan-
creatitis at age 17 and hypertension at age 40, and the
family history indicated that his nephew had IgA
nephropathy. The patient occasionally consumes alcohol,
but doesn’t smoke. The patient visited a local doctor and
underwent a renal biopsy for suspected active nephritis
because of the finding (Table 1) of hematuria 3? protein
from pooled urine 0.78 g/day and a plasma creatinine (Cr)
level of 1.16 mg/dl [estimated glomerular filtration rate
(eGFR) 71 ml/min/1.73 m2]. Pathologic examination
revealed IgA nephropathy with partial cellular crescent
formation in 1 of the 12 glomeruli, slight mesangial matrix
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expansion, and mild atrophy of the renal tubule and
interstitium. He was followed up without treatment, and the
urinary abnormalities resolved spontaneously. He stopped
visiting the hospital 3 years after the first visit because of
the repeated negative urine analysis and did not visit any
other hospital thereafter. He continued to undergo routine
medical examinations, which were intermittently positive
for microhematuria and proteinuria. His next visit to a
medical institution was in 2002 at 38 years of age and
revealed urine protein 2?, urine occult blood 1?, plasma
Cr 1.13 mg/dl and hypertension. An angiotensin receptor
blocker (ARB) was started. After that, he saw a doctor
regularly, but hematuria and proteinuria became gradually
worse. A relapse of IgA nephropathy was suspected. In
March 2009, he was admitted to a hospital for renal biopsy
to evaluate the progression of IgA nephropathy.
The patient’s general condition at the time of hospital-
ization was height 163.0 cm, weight 55.0 kg, body mass
index 20.7 kg/m2, blood pressure 116/72 mmHg, heart rate
83 beats/min and temperature 36.6 C. He was lucid with
no sign of anemia in the palpebral conjunctiva. No swelling
of the throat, abnormal chest auscultation, hard and tender
points in the abdominal area or edema of the extremities
was observed. Medical examinations (Table 1) revealed
urine protein 3? (0.90 g/day), urine occult blood 3? (RBC
10–19/HPF) and serum Cr 1.63 mg/dl.
Renal biopsy (Fig. 1) showed 4 global scleroses, 3 cel-
lular crescent formations and 3 adhesions in 28 glomeruli;
moderate expansion of the mesangial matrix; moderate
tubular atrophy with mild cell infiltration in the interstit-
ium; and moderate arteriolosclerosis and thickening of
interlobular arteries. Immunostaining of IgA confirmed the
diagnosis of active chronic-progressive IgA nephropathy.
After admission, the patient was treated with tonsillec-
tomy and steroid pulse therapy. Steroid pulse therapy was
given as follows: methylprednisolone was administered
continuously at a pulsed dose of 500 mg/day for 3 days,
followed by oral prednisolone at a dose of 30 mg contin-
uously for 3 weeks. After completion of the third course,
oral prednisolone was initiated at a dose of 30 mg/day
every other day after treatment and tapered by 5 mg every
2 months. The after-treatment follow-up was continued for
1 year. The patient underwent tonsillectomy after dis-
charge from the hospital (day 75) and was then followed up
at the outpatient clinic. He completed oral prednisolone
treatment in approximately a year, but continued taking an
ARB during the follow-up period. Clinical remission was
achieved 7 months after the initiation of therapy (Table 1),
and hematuria and proteinuria were no longer observed in
this 3-year follow-up period (Fig. 2).
Discussion
It is well known that patients with IgA nephropathy
experience different disease courses. Our patient had a
peculiar clinical course. On diagnosis of mild IgA
nephropathy and follow-up without treatment, he tempo-
rally underwent spontaneous remission, although relapse
occurred 14 years later. As a result of his long-term sur-
vival with moderate renal failure, the second renal biopsy
showed a composite result of more advanced chronic
Table 1 The clinical course of laboratory findings
1985 (22 years old)
First renal biopsy
2000 (35 years old)
Follow-up of local
doctor
2008 (43 years old)
Second renal biopsy
2009 (44 years old)
Clinical remission
7 months after steroid
pulse therapy
2013 (43 years old)
The last outpatient
visit













Serum Cr (mg/dl) 1.16 1.30 1.63 1.20 1.40
eGFR (ml/min/1.73 m2) 71.0 48.5 38.7 53.0 45.1
Fig. 1 Renal biopsy findings. PAS staining showed moderate tubular
atrophy and globally sclerotic glomeruli
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manifestation and active disease with decreased eGFR of
38.7 ml/min.
Since Hotta et al. [7] reported the use of tonsillectomy
and steroid pulse therapy in patients with IgA nephropathy
in 2001, the therapy has been used extensively in patients
with IgA nephropathy mainly in Japan as well as in other
countries. As mentioned above, some patients have spon-
taneous remission; therefore, the criteria for its use have
not yet been established.
There are several reports on the efficacy of tonsillec-
tomy and steroid pulse therapy for nonadvanced IgA
nephropathy, especially in Japan [5, 6]. Although the
indication of tonsillectomy and steroid pulse therapy
remains controversial, it is hypothesized that there is a
‘‘point of no return’’ in progressive IgA nephropathy after
which progression to end-stage renal disease (ESRD)
becomes inevitable. Studies on treatment for advanced IgA
nephropathy include a retrospective cohort study by Sato
[7] who investigated 70 patients with baseline serum Cr of
1.5 mg/dl or higher, who were assigned to the tonsillec-
tomy and steroid pulse therapy, oral steroid or control
groups and followed up for a mean of 5.9 years. The results
showed that patients with baseline serum Cr of 1.5–2.0 mg/
dl in the tonsillectomy and steroid pulse therapy group had
decreased progression of ESRD compared with the other
two groups, whereas there was no significant difference in
the outcome in patients with baseline plasma Cr of
C2.0 mg/dl. Komatsu et al. [8] reported similar results,
indicating that tonsillectomy and steroid pulse therapy are
not indicated in patients with a Cr level above 2.0 mg/dl.
Our patient was considered to have a poor prognosis as
he had a long disease duration of 24 years and advanced
renal impairment with eGFR of 38.7 ml/min and plasma Cr
of 1.41 mg/dl. However, the IgA nephropathy continued to
present disease activity; therefore, we performed tonsil-
lectomy and steroid pulse therapy. Remission of the urinary
findings was achieved, and progressive deterioration of
renal function was successfully prevented. Although a
chronic manifestation such as glomerulosclerosis
remained, eGFR improved following suppression of acute
inflammatory symptoms. Hotta et al. [9] reported that
tonsillectomy and steroid pulse therapy were associated
with histological improvements such as reduced mesangial
proliferation and interstitial fibrosis [10]. Subsequent
development of nephrosclerosis may be reduced mainly by
management of hypertension and nutritional therapy with
protein and sodium restriction preventing hyperfiltration in
residual glomeruli.
This case report shows the possibility of the effect of
tonsillectomy and steroid pulse therapy for IgA nephrop-
athy with long disease duration and decreased renal func-
tion if the activity of IgA nephropathy remains.
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